← Back to Clinical Trials
Recruiting NCT07474935

NCT07474935 Targeting Real World Usage In Stroke Treatment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07474935
Status Recruiting
Phase
Sponsor Phenox GmbH
Condition Saccular and Fusiform Aneurysms
Study Type OBSERVATIONAL
Enrollment 5,000 participants
Start Date 2026-01-29
Primary Completion 2036-01

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Aneurysm Treatment with a Neurovascular Flow DiverterDissection Treatment with a Neurovascular Flow DiverterPerforation Treatment with a Neurovascular Flow Diverter

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 5,000 participants in total. It began in 2026-01-29 with a primary completion date of 2036-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

TRUST Registry is an observational, prospective, long-term, post-market surveillance registry of subjects treated with WallabyPhenox flow modulation devices, stent systems, bifurcation aneurysm implants including their HPC variants (Hydrophilic Polymer Coating) where applicable as well as coil systems, and other adjunctive medical devices. The overarching purpose of this registry is to carry out a proactive gathering, recording, and analysis of data on the safety, performance and usability of the devices as applied within the routine practice of the participating registry sites.

Eligibility Criteria

Inclusion Criteria: * Subject treated or intended to be treated with at least one target registry device during the procedure (i.e., at least one attempt of introduction into the vasculature of the subject), * Non-opposition to data collection or informed consent provided by the subject or legal representative as per country-specific legislation. Exclusion Criteria: * Participation in an interventional study modifying standard care management for all relevant indications,

Frequently Asked Questions

Who can join the NCT07474935 clinical trial?

This trial is open to participants of all sexes, studying Saccular and Fusiform Aneurysms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07474935 currently recruiting?

Yes, NCT07474935 is actively recruiting participants. Visit ClinicalTrials.gov or contact Phenox GmbH to inquire about joining.

Where is the NCT07474935 trial being conducted?

This trial is being conducted at Brest, France, Paris, France, Erfurt, Germany, Hamburg, Germany and 9 additional locations.

Who is sponsoring the NCT07474935 clinical trial?

NCT07474935 is sponsored by Phenox GmbH. The trial plans to enroll 5,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology